Biotech Values

[ThomasS]

VRTX: In all seriousness, considering they have improved HCV treatment by a factor of 3+, (for the worst version of HCV) they should be granted FDA Approval without further studies, other than post-marketing studies/additional safety studies.
Think about it: 50% reduction in treatment length with an @50% better efficacy. That's almost the double-double I alluded to months ago.

"Typically, not more than 50 percent of patients taking standard treatments see their virus eradicated."
---That implies @50% efficacy from SOC, which is over-estimating.